(s)-n-(4-carbamoylphenyl)-8-cyclopropyl-7-(naphthalen-1-ylmethyl)-5-oxo-2,3-dihydro-5h-thiazolo[3,2-a]pyridine-3-carboxamide, a better inhibitor of sars-cov-2 spike glycoprotein than some standard drugs: a computational prediction

The appearance of severe acute respiratory syndrome coronavirus 2 (covid-19) is at its peak; with the growing number of people infected with covid-19, there is an urgent need to find effective treatments for this outbreak. the current situation appears to call for drug repurposing. in our hunt for a viable medication against this virus, we used an in-silico strategy to test four conventional medicines, including ritonavir and hydroxychloroquine, against the spike glycoprotein of covid-19. a docking simulation was performed to assess the drug's binding affinity. we discovered a single medication compound 36 against sars-coronavirus spike glycoprotein. the compound was found to have a strong binding affinity against the target protein. the chemical was discovered to have a high affinity for the target protein. furthermore, no conventional medicines efficiently bonded to the sars-coronavirus spike glycoprotein. the current investigation concluded that the compound 36 is a highly stable anti-sars-coronavirus spike glycoprotein medication. furthermore, none of the standard drugs had a high affinity for the sars-coronavirus spike glycoprotein binding site.